Literature DB >> 16254307

ASCOT: a tale of two treatment regimens: odds are that it's hype.

Martin G Duerden.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16254307      PMCID： PMC1273494          DOI： 10.1136/bmj.331.7523.1022-b

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  The PROGRESS trial three years later: time for more action, less distraction.

Authors:  Stephen Macmahon; Bruce Neal; Anthony Rodgers; John Chalmers
Journal:  BMJ       Date:  2004-10-23

2.  ASCOT: a tale of two treatment regimens.

Authors:  Claire McDougall; Adrian J B Brady; John R Petrie
Journal:  BMJ       Date:  2005-10-15

Review 3.  How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?

Authors:  Nick Freemantle
Journal:  BMJ       Date:  2005-10-08

4.  Optimisation of antihypertensive treatment by crossover rotation of four major classes.

Authors:  J E Dickerson; A D Hingorani; M J Ashby; C R Palmer; M J Brown
Journal:  Lancet       Date:  1999-06-12       Impact factor: 79.321
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.